Get the Stockscreener App
4.55
14.42%
-0.79
Cumberland Pharmaceuticals Inc stock is traded at $4.55, with a volume of 909.47K.
It is down -14.42% in the last 24 hours and up +92.83% over the past month.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.
See More
Previous Close:
$5.34
Open:
$5.22
24h Volume:
909.47K
Relative Volume:
0.30
Market Cap:
$74.99M
Revenue:
$37.79M
Net Income/Loss:
$-10.38M
P/E Ratio:
-6.2329
EPS:
-0.73
Net Cash Flow:
$-1.00M
1W Performance:
+102.21%
1M Performance:
+92.83%
6M Performance:
+208.78%
1Y Performance:
+131.98%
1-Day Range:
$4.4202
$5.25
1-Week Range:
$2.08
$6.43
52-Week Range:
$1.04
$6.43
Cumberland Pharmaceuticals Inc Stock (CPIX) Company Profile
Name
Cumberland Pharmaceuticals Inc
Sector
Phone
615-255-0068
Address
2525 WEST END AVENUE, NASHVILLE,, TN
Compare CPIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CPIX
Cumberland Pharmaceuticals Inc
|
4.50 | 74.99M | 37.79M | -10.38M | -1.00M | -0.73 |
|
ZTS
Zoetis Inc
|
172.28 | 78.56B | 9.15B | 2.43B | 2.31B | 5.32 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.56 | 43.15B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
9.55 | 43.00B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.84 | 19.59B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
123.69 | 15.24B | 2.24B | 385.90M | 440.10M | 3.73 |
Cumberland Pharmaceuticals Inc Stock (CPIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-12-12 | Reiterated | UBS | Neutral |
| Feb-01-11 | Reiterated | UBS | Neutral |
| Dec-16-10 | Downgrade | UBS | Buy → Neutral |
| Aug-17-10 | Downgrade | Jefferies | Buy → Hold |
| Aug-17-10 | Reiterated | Morgan Joseph | Buy |
| Aug-17-10 | Reiterated | UBS | Buy |
| May-14-10 | Reiterated | Morgan Joseph | Buy |
View All
Cumberland Pharmaceuticals Inc Stock (CPIX) Latest News
Stock Performance Spotlight: Cumberland Pharmaceuticals Inc (CPIX) Ends the Day at 5.34, Up by 5.12 - The Dwinnex
Cumberland Pharmaceuticals (NASDAQ:CPIX) Now Covered by Analysts at StockNews.com - Armenian Reporter
Financial Survey: Cumberland Pharmaceuticals (NASDAQ:CPIX) versus Skye Bioscience (NASDAQ:SKYE) - Defense World
Adversity is less terrifying than hope: Cumberland Pharmaceuticals Inc (CPIX) - SETE News
Cumberland Pharma (CPIX) Achieves Key Milestone, Stock Jumps - Stocks Telegraph
Cumberland Pharmaceuticals sees nearly 50 million shares trade - Nashville Post
Cumberland Pharmaceuticals reports data from trial of ifetroban for DMD - Yahoo Finance
Pharma Stock Soars On Phase 2 Announcement - The Globe and Mail
Cumberland Pharmaceuticals stock soars - Nashville Post
Uncovering the Potential of Cumberland Pharmaceuticals Inc (CPIX) Stock - The InvestChronicle
Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease - Benzinga
Stock market news: Nuvve Holding +47.92%, Flexsteel Industries +28.15% among top gainers during mid day trading - Business Upturn
Cumberland Pharmaceuticals Inc (CPIX) Stock Price and Analyst Predictions - The News Heater
Is CPIX’s price to cash per share ratio a concern for investors? - US Post News
Cumberland reports progress in DMD heart disease trial - MSN
Cumberland's Duchenne drug improves blood flow from heart in phase 2 trial - Fierce Biotech
Cumberland Vaults on DMD Test Results - Baystreet.ca
Cumberland Pharmaceuticals Announces Phase 2 Fight Dmd Trial Results For Duchenne Muscular Dystrophy Heart Disease - Marketscreener.com
Cumberland's DMD Heart Disease Drug Shows Breakthrough 5.4% LVEF Improvement in Phase 2 | CPIX Stock News - StockTitan
Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Crosses Above Two Hundred Day Moving Average – Time to Sell? - Defense World
Hepatorenal Syndrome Treatment Market: Increasing Demand, Market Size, and Foreseen Trends for 2024-2029 - openPR
Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs - openPR
StockNews.com Initiates Coverage on Cumberland Pharmaceuticals (NASDAQ:CPIX) - Defense World
Cumberland Pharmaceuticals (NASDAQ:CPIX) Shares Pass Above Two Hundred Day Moving Average – Here’s What Happened - Defense World
SAP (SAP) Expected to Announce Earnings on Tuesday - Defense World
Advancements in Ocular Hypertension Clinical Trial Pipeline - GlobeNewswire
3 US Penny Stocks With Market Caps Over $30M - Yahoo Finance
Dilated Cardiomyopathy Pipeline Overview 2024: FDA Approvals and Key Developments | Vericel Corporation, AstraZeneca, Pfizer, Zensun Shanghai Sci & Tech Co Ltd, Capricor Therapeutics - The Globe and Mail
Improved Revenues Required Before Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Stock's 26% Jump Looks Justified - Simply Wall St
Evolving Landscape of Cardiology Segment: Key Market Insights of Latest Published Rare Cardiovascular Diseases Report — Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy | DelveInsight - GlobeNewswire Inc.
CPIX stock touches 52-week high at $3.09 amid market rally - Investing.com
scPharmaceuticals Provides Preliminary Financial Results for Fourth Quarter and Full Year 2024On January 10, 2025, scPharmaceuticals Inc. (NASDAQ: SCPH) released an 8-K filing containing preliminary unaudited financial information for the quarter and - Defense World
Cumberland Pharmaceuticals (NASDAQ:CPIX) Coverage Initiated at StockNews.com - Defense World
Cumberland Pharmaceuticals director Krogulski buys $8,209 in stock - Investing.com India
Cumberland Pharmaceuticals director James Jones acquires $1,317 in stock By Investing.com - Investing.com Nigeria
Cumberland Pharmaceuticals CEO AJ Kazimi purchases $1317 in stock By Investing.com - Investing.com Nigeria
Cumberland Pharmaceuticals director Krogulski buys $8,209 in stock By Investing.com - Investing.com Canada
Cumberland Pharmaceuticals director Caroline Young acquires $256 in stock By Investing.com - Investing.com Canada
Cumberland Pharmaceuticals director James Jones acquires $1,317 in stock - Investing.com India
Cumberland Pharmaceuticals CEO AJ Kazimi purchases $1317 in stock - Investing.com
Cumberland Pharmaceuticals (NASDAQ:CPIX) Now Covered by StockNews.com - Defense World
Athira Pharma (NASDAQ:ATHA) Stock Quotes, Forecast and News Summary - Benzinga
StockNews.com Begins Coverage on Cumberland Pharmaceuticals (NASDAQ:CPIX) - Defense World
Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Crosses Above 200-Day Moving Average – Here’s Why - Defense World
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
3 Penny Stocks to Watch Now, 12/12/24 - TipRanks
3 Promising Penny Stocks With Market Caps Under $2B In US - Simply Wall St
FDA APPROVES ACETADOTE® sNDA - Citizentribune
Cumberland Pharmaceuticals stock pops - Nashville Post
Cumberland Stock Soars 90% After FDA Approval for Acetadote Dosing Change - GuruFocus.com
Stock Skyrockets! Discover What’s Fueling This Company’s Massive Surge. - elblog.pl
Cumberland Pharmaceuticals Inc Stock (CPIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):